Mushegh А Sahakyan1,2, Artak Gabrielyan3, Hmayak Petrosyan3, Shushan Yesayan4,5, Sevak S Shahbazyan6,7, Arthur M Sahakyan8,3. 1. Department of Surgery N1, Yerevan State Medical University after M.Heratsi, Yerevan, Armenia. sahakyan.mushegh@gmail.com. 2. Department of General and Laparoscopic Surgery, Central Clinical Military Hospital, Yerevan, Armenia. sahakyan.mushegh@gmail.com. 3. Department of General and Abdominal Surgery, ArtMed MRC, Yerevan, Armenia. 4. Department of Anesthesiology and Intensive Care, ArtMed MRC, Yerevan, Armenia. 5. Department of Anesthesiology and Intensive Care, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. 6. Department of General and Laparoscopic Surgery, Central Clinical Military Hospital, Yerevan, Armenia. 7. Department of General and Thoracic Surgery, Yerevan State Medical University after M.Heratsi, Yerevan, Armenia. 8. Department of Surgery N1, Yerevan State Medical University after M.Heratsi, Yerevan, Armenia.
Abstract
PURPOSE: This study reports single-surgeon experience with extended gastrectomy including en-bloc resection of adjacent organs/structures for T4b stage gastric adenocarcinoma. Time-related changes in patient selection criteria and outcomes were also analyzed. METHODS: All consecutive gastrectomies for adenocarcinoma performed between May 2004 and December 2017 were extracted from prospectively collected database to study surgical and oncologic results. Time-related changes in outcomes were examined according to three time periods. RESULTS: Five hundred eighty-seven gastrectomies were performed throughout the study period including 87 (14.8%) extended resections. The latter most often included pancreatosplenectomy, colon, and liver resections (21, 16, and 11 patients, respectively) resulting in similar postoperative outcomes and survival. Extended gastrectomy was associated with larger tumor size (8.4 vs 5.6 cm), performing total gastrectomy (55.2 vs 35.2%, p < 0.01) and increased blood loss (375 vs 150 ml, p < 0.01) compared with standard gastrectomy. Larger experience in extended gastrectomy allowed for expanding patient selection criteria, considering complex resections and extensive lymphadenectomy. Median and 3-year survival following extended gastrectomy for T4b adenocarcinoma were 14 months and 18%, respectively, which was comparable to standard gastrectomy for T4a adenocarcinoma (p = 0.48). Obesity, nodal stage and type of gastrectomy were associated with survival in T4b adenocarcinoma in the univariable analysis. Obesity and N3a and N3b stages were independent predictors in the multivariable model. CONCLUSIONS: Extended gastrectomy for T4b gastric adenocarcinoma provides satisfactory surgical outcomes even with expanded patient selection criteria and regardless of the organ involved. Given its poor prognosis, neoadjuvant therapy should be considered to improve the long-term oncologic results.
PURPOSE: This study reports single-surgeon experience with extended gastrectomy including en-bloc resection of adjacent organs/structures for T4b stage gastric adenocarcinoma. Time-related changes in patient selection criteria and outcomes were also analyzed. METHODS: All consecutive gastrectomies for adenocarcinoma performed between May 2004 and December 2017 were extracted from prospectively collected database to study surgical and oncologic results. Time-related changes in outcomes were examined according to three time periods. RESULTS: Five hundred eighty-seven gastrectomies were performed throughout the study period including 87 (14.8%) extended resections. The latter most often included pancreatosplenectomy, colon, and liver resections (21, 16, and 11 patients, respectively) resulting in similar postoperative outcomes and survival. Extended gastrectomy was associated with larger tumor size (8.4 vs 5.6 cm), performing total gastrectomy (55.2 vs 35.2%, p < 0.01) and increased blood loss (375 vs 150 ml, p < 0.01) compared with standard gastrectomy. Larger experience in extended gastrectomy allowed for expanding patient selection criteria, considering complex resections and extensive lymphadenectomy. Median and 3-year survival following extended gastrectomy for T4b adenocarcinoma were 14 months and 18%, respectively, which was comparable to standard gastrectomy for T4a adenocarcinoma (p = 0.48). Obesity, nodal stage and type of gastrectomy were associated with survival in T4b adenocarcinoma in the univariable analysis. Obesity and N3a and N3b stages were independent predictors in the multivariable model. CONCLUSIONS: Extended gastrectomy for T4b gastric adenocarcinoma provides satisfactory surgical outcomes even with expanded patient selection criteria and regardless of the organ involved. Given its poor prognosis, neoadjuvant therapy should be considered to improve the long-term oncologic results.
Authors: D K Dhar; H Kubota; M Tachibana; S Kinugasa; R Masunaga; M Shibakita; H Kohno; N Nagasue Journal: J Surg Oncol Date: 2001-04 Impact factor: 3.454
Authors: Mi Sun Kim; Joon Seok Lim; Woo Jin Hyung; Yong Chan Lee; Sun Young Rha; Ki Chang Keum; Woong Sub Koom Journal: World J Gastroenterol Date: 2015-03-07 Impact factor: 5.742
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Heewon Kim; Yunji Hwang; Hokyung Sung; Jieun Jang; Choonghyun Ahn; Sang Gyun Kim; Keun-Young Yoo; Sue K Park Journal: Cancer Res Treat Date: 2017-06-09 Impact factor: 4.679